Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Novantrone (mitoxantrone HCl) Injection February 2009
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
Clinically feasible MTR is sensitive to cortical demyelination in MS.
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
Rituximab and multiple sclerosis.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Alemtuzumab benefits hard-to-treat MS patients
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
Treatment of neurological injury with thymosin β4.
Society for Neuroscience Annual Meeting
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Rituximab product approval information - Licensing action

Pages